Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 151 AL 165

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Hazan J, Liu KY, Howard R.

Alzheimers Dement. 2026 Jul;22(7):e71643. doi: 10.1002/alz.71643.

Efficacy of non-invasive brain stimulation in Alzheimer's disease: An umbrella review of meta-analyses

Tang Y, Huang L, Li W, Gao T, Shi N, Zhu Y, Wang Y, Nan J, Zhu Y, Li J, Ma Y.

Neurosci Biobehav Rev. 2026 Oct;189:106844. doi: 10.1016/j.neubiorev.2026.106844. Epub 2026 Jul 3.

HDAC11 as a potential therapeutic target for Alzheimer's disease

Zhang W, Wang Y, Tocci D, Wang C, Zhang C.

Drug Discov Today. 2026 Jul;31(4):104730. doi: 10.1016/j.drudis.2026.104730. Epub 2026 Jul 14.

Preclinical evidence for icariin in Alzheimer's disease: Methodological quality, efficacy, and mechanisms

Chen ML, Hao LY, Zhang ZH, Xu HF, Li HF, Wen L, Zheng GQ.

Ageing Res Rev. 2026 Oct;121:103228. doi: 10.1016/j.arr.2026.103228. Epub 2026 Jul 5.

Restoring the balance: Resistance exercise-induced insulin-like growth factor-1 restores PI3K/Akt and MAPK/ERK cross-talk to ameliorate Alzheimer's disease

Liu Z, Tong X, Li X, Duan X, Yang Y, Chen F, Liu Y, Tao X, Liu W.

Ageing Res Rev. 2026 Oct;121:103239. doi: 10.1016/j.arr.2026.103239. Epub 2026 Jul 7.

Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway and Drug Repurposing

Dubey A, Chaurasia A, Ansari Z, Kushwaha SK, Saraf I, Kashaw S, Swami R, Kushwah V.

Drug Dev Res. 2026 Aug;87(5):e70344. doi: 10.1002/ddr.70344.

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes

Caselli RJ, Geldmacher DS, Schilling TB.

Neurologist. 2026 Jul 1;31(4):129-135. doi: 10.1097/NRL.0000000000000679.

A nose-to-brain drug delivery system targeting mitochondrial dysfunction: application potential and future prospects of chitosan nanogels in Alzheimer's disease

Huang Q, Zuo Y, Xie Y, Liu Z, Wang L, Xu H, Yu M, Liu C.

Biomater Sci. 2026 Aug 11;14(16):4164-4196. doi: 10.1039/d6bm00624h.

Repurposing apremilast for alzheimer's disease: multitarget modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling

Choudhary N, Rana S, Vashisht K, Sharma V, Bhatia V, Ashawat MS, Kushawaha SK.

Metab Brain Dis. 2026 Jul 11;41(1):163. doi: 10.1007/s11011-026-01906-9.

Exploring thiazole conjugates as cholinesterase inhibitors for Alzheimer's disease treatment

Dabas A, Yadav P, Singh R.

Future Med Chem. 2026 Aug;18(16):2187-2201. doi: 10.1080/17568919.2026.2699679. Epub 2026 Jul 11.

Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Literature Review

Petrov W, Ślebioda D, Kozińska R, Kukla K, Petrov P, Sroka M, Tesyna J, Puźniak G, Kudliński M, Rejda T, Skowron I, Chłopaś-Konowałek A.

Int J Mol Sci. 2026 Jun 25;27(13):5733. doi: 10.3390/ijms27135733.

Leveraging Advanced AI Frameworks for Dual PPAR α/γ Agonist Discovery in Alzheimer's Disease

Chaturvedi N, Mishra V, Haque S, Khatoon S, Rawal K, Kumar V.

ACS Chem Neurosci. 2026 Aug 5;17(15):2802-2817. doi: 10.1021/acschemneuro.6c00148.

Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease

Shi Y, Liao X, Yu G.

ChemMedChem. 2026 Jul 29;21(14):e70384. doi: 10.1002/cmdc.70384.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias